We are excited to announce OCCIDENT’s latest investment in EBAMed, a Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias using proton therapy.
The € 14.35 million Series A round was led by Panakès Partners, together with the EIC Fund and participation from EFI Lake Geneva Ventures, LIFTT and OCCIDENT. The round was also supported by existing investors, including Mayo Clinic.
The funds will be used to bring EBAMed’s CardioKit system – a device that automatically adjusts cardiac radiation ablation systems for cardiac motion and increases external beam delivery precision – to completion of its first-in-human trials.
The development of a radiation therapy approach, combined with a unique motion monitoring and gating solution, will address an important need for alternatives to either drug therapy or catheter-based ablation, and for reduced radiation of healthy myocardium.
More information in the press release under the following Link
More about EBAMed
